Anti-IGF1 Receptor (phospho Y1131+ Y1135+ Y1136) + INSR (phospho Y1158+ Y1162+ Y1163) antibody,Abcam,AB5681

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of IR/IGF1R that contains tyrosines 1158, 1162 and 1163 of the human insulin receptor (IR) as numbered according to Ebina, et al. (1146, 1150 and 1151 according to Ullrich, et al.). The corresponding residues in the IGF1R are 1131, 1135 and 1136. The sequence is conserved in human, mouse and rat for both the IR and IGF1R. The two relevant papers are: Ebina, Y., et al. (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40(4):747-758. Ullrich, A., et al. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313(6005):756-761. There are a long and a short isoform of this protein. This is why we are listing 1158, 1162 and 1163 in the name (where these phospho sites in the long isoform) as well as 1146, 1150 and 1151 (for the short isoform).

Host

Rabbit

Reactivity

Human

Application

WB

Platform ID

BAB285995743

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-IGF1 Receptor (phospho Y1131+ Y1135+ Y1136) + INSR (phospho Y1158+ Y1162+ Y1163) antibody
Cat. No.AB5681
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB
ClonalityPolyclonal
Concentration0.8 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human IGF1R phospho Y1131 + Y1135 + Y1136. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Immunogen
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.3 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.. When present in a hybrid receptor with INSR, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. See full target information IGF1R phospho Y1131 + Y1135 + Y1136

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.